Physician profile
Charles A Mitchell, III
NPI 1245238567
$5,111.65
in general payments reported to CMS, 2019-2025
25 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $212 · 2021: $650 · 2022: $1,114 · 2023: $1,262 · 2024: $664 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,934 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,933.92 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,483.05 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $550.27 | 2020-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $439.36 | 2023-2025 | Tremfya |
| Galderma Laboratories, L.P. | $329.43 | 2021-2025 | Nemluvio, Oracea, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $323.96 | 2021-2024 | Jublia, Arazlo |
| Pfizer INC. | $269.93 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $238.75 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $191.18 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $145.13 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $137.53 | 2022-2025 | |
| Amgen INC. | $136.30 | 2021-2024 | Otezla |
| Ucb, INC. | $125.09 | 2023-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $122.69 | 2019-2025 | |
| Leo Pharma INC. | $101.77 | 2022-2023 | Adbry |
| Journey Medical Corporation | $82.80 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $79.61 | 2023-2025 | Hadlima |
| Lilly USA, LLC | $69.05 | 2019-2024 | Taltz |
| Dermira, INC. | $53.64 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.93 | 2023-2025 | Spevigo |
| Incyte Corporation | $48.61 | 2024-2025 | Opzelura |
| Celgene Corporation | $36.07 | 2019 | |
| Epi Health, LLC | $28.73 | 2021 | |
| Allergan, INC. | $24.34 | 2022 | |
| Lnhc, INC | $23.29 | 2025 | Zelsuvmi |
| Almirall LLC | $18.14 | 2024 | Seysara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.